Published in Life Sci on April 29, 2006
Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol (2009) 1.10
Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol (2009) 1.04
Validity of SW982 synovial cell line for studying the drugs against rheumatoid arthritis in fluvastatin-induced apoptosis signaling model. Indian J Med Res (2014) 0.82
Circulating Markers Reflect Both Anti- and Pro-Atherogenic Drug Effects in ApoE-Deficient Mice. Biomark Insights (2008) 0.75
Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells. Sci Rep (2017) 0.75
Label-free immunodetection with CMOS-compatible semiconducting nanowires. Nature (2007) 5.25
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Detecting protein-protein interactions with a green fluorescent protein fragment reassembly trap: scope and mechanism. J Am Chem Soc (2005) 2.95
Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem Int Ed Engl (2005) 2.65
Targeting protein prenylation for cancer therapy. Nat Rev Cancer (2011) 2.60
Water gelation by small organic molecules. Chem Rev (2004) 2.45
Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Mol Cell Biol (2005) 2.31
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10
Synthetic non-peptide mimetics of alpha-helices. Chem Soc Rev (2007) 2.04
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res (2002) 1.79
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene (2005) 1.70
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2005) 1.58
Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. Angew Chem Int Ed Engl (2003) 1.55
Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J R Soc Interface (2006) 1.53
Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J Am Chem Soc (2002) 1.50
Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew Chem Int Ed Engl (2005) 1.49
Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics. Curr Opin Chem Biol (2010) 1.47
Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl (2002) 1.47
Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. J Am Chem Soc (2005) 1.46
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem (2002) 1.43
Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol (2004) 1.40
The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. J Biol Chem (2010) 1.39
Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2006) 1.38
FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Am Chem Soc (2006) 1.36
Helix mimetics as inhibitors of the interaction of the estrogen receptor with coactivator peptides. Angew Chem Int Ed Engl (2007) 1.34
Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. J Am Chem Soc (2005) 1.34
In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest (2003) 1.33
Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Mol Cell Biol (2007) 1.32
Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev (2006) 1.28
Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Res (2003) 1.24
Protein-protein interaction inhibitors: small molecules from screening techniques. Curr Top Med Chem (2007) 1.23
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res (2011) 1.23
Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem (2008) 1.21
Inhibition of angiogenesis by Abeta peptides. Angiogenesis (2004) 1.19
Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene (2005) 1.18
A peptidomimetic approach to targeting pre-amyloidogenic states in type II diabetes. Chem Biol (2009) 1.18
Pattern recognition of proteins based on an array of functionalized porphyrins. J Am Chem Soc (2006) 1.18
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs (2010) 1.16
Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2010) 1.15
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2005) 1.15
Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg Med Chem Lett (2007) 1.15
Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Mol Cell Biol (2009) 1.15
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood (2003) 1.15
Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Investig Drugs (2003) 1.13
Synthesis of a 2,3';6',3''-terpyridine scaffold as an alpha-helix mimetic. Org Lett (2005) 1.12
Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res (2011) 1.12
Synthetic alpha-helix mimetics as agonists and antagonists of islet amyloid polypeptide aggregation. Angew Chem Int Ed Engl (2010) 1.11
XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses (2002) 1.10
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem (2009) 1.10
Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol (2009) 1.10
Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des (2010) 1.10
A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res (2013) 1.09
RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res (2012) 1.05
p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53. Mol Cancer Ther (2005) 1.05
Benzoylurea oligomers: synthetic foldamers that mimic extended alpha helices. Angew Chem Int Ed Engl (2007) 1.05
Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res (2004) 1.05
Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. J Clin Invest (2008) 1.04
Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle (2009) 1.03
Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem (2008) 1.03
Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene (2002) 1.02
Modifications of the GSK3beta substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics. Bioorg Med Chem Lett (2007) 1.01
Pattern-based detection of different proteins using an array of fluorescent protein surface receptors. J Am Chem Soc (2004) 1.01
Protein surface recognition and proteomimetics: mimics of protein surface structure and function. Curr Opin Chem Biol (2005) 1.01
Deficiency of the transcriptional regulator p8 results in increased autophagy and apoptosis, and causes impaired heart function. Mol Biol Cell (2010) 0.99
Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr Top Med Chem (2002) 0.99
EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene (2004) 0.97
In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg Med Chem (2004) 0.95
Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem (2006) 0.95
alpha-Helix mimetics as inhibitors of protein-protein interactions. Biochem Soc Trans (2008) 0.95
Protein recognition and denaturation by self-assembling fragments on a DNA quadruplex scaffold. Angew Chem Int Ed Engl (2007) 0.94
Digital analysis of protein properties by an ensemble of DNA quadruplexes. J Am Chem Soc (2009) 0.94
Controlling curvature in a family of oligoamide alpha-helix mimetics. Angew Chem Int Ed Engl (2008) 0.93
Rigid macrocyclic triamides as anion receptors: anion-dependent binding stoichiometries and 1H chemical shift changes. J Am Chem Soc (2003) 0.93
Role of SREBP-1 in the development of parasympathetic dysfunction in the hearts of type 1 diabetic Akita mice. Circ Res (2009) 0.93
Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness. Circulation (2003) 0.93
Recent advances in the development of aryl-based foldamers. Chem Soc Rev (2009) 0.92
Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. Angew Chem Int Ed Engl (2005) 0.92
Amphiphilic α-helix mimetics based on a benzoylurea scaffold. Org Biomol Chem (2012) 0.92